Similarly, transthyretin was identified in AD and mild cognitive impairment CSF62 and in our OPLS-DA analysis; serum amyloid A4 protein contributed to variance in our OPLS-DA analysis; complement component C3, however, was not included on our panel. This evidence concerns the gene C3 and Alzheimer disease.